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Abstract
Until recently, only one study was published on cognitive-behavioral therapy (CBT) of 
posttraumatic stress disorder (PTSD) in individual therapy via videoconference (Germain, 
Marchand, Bouchard, Drouin, & Guay, 2009); however, it only assessed the posttreatment effect. 
This study presents the follow-up of Germain et al.’s (2009) study. The main goal was to compare 
the effectiveness after six months of CBT for PTSD either face-to-face (n = 24) or by 
videoconference (n = 12). Each participant received CBT for 16 to 25 weeks and completed 
various questionnaires before and after treatment and at a six-month follow-up. The two treatments 
had equivalent levels of symptom reduction (Modified PTSD Symptom Scale: η2 < 0.01, p > .05) 
and proportion of patients with a clinically significant change in symptoms (42% for face-to-face 
vs. 38% for videoconferencing, p > .05). Thus, CBT for PTSD via videoconference seems to be a 
viable alternative when adequate face-to-face treatments are less available.
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Currently, cognitive-behavioral therapy (CBT) is the most empirically validated treatment 
for posttraumatic stress disorder (PTSD); its efficacy was confirmed in two meta-analyses 
(Bradley, Greene, Russ, Dutra, & Westen, 2005; Van Etten & Taylor, 1998). However, access 
to state-of-the-art psychotherapy such as CBT treatment for PTSD is still limited and 
uneven. For example, it was shown that less than 20% of the hospitals in Canada had an 
anxiety disorders clinic and these clinics were mainly in urban areas (Swinson, Cos, Kerr, & 
Kuch, 1992). Similar situations can be expected in many industrialized countries. Access to 
these specialized services can therefore be problematic for individuals living outside major 
urban centers, and especially in rural regions. This uneven access to professional resources is 
also exacerbated by the fact that some people with severe or chronic problems cannot travel 
to the available resources for a variety of reasons (e.g., disability, avoidance behaviors, lack 
of energy; Riemer-Reiss, 2000).
In that context, telepsychotherapy offered by videoconference constitutes an interesting 
solution. Videoconferencing is a technological procedure that allows individuals to see and 
hear each other on a computer monitor or video screen in real time. Hence, it enables 
individuals in different locations to interact simultaneously. Telepsychotherapy via 
videoconference can thus serve as a solution to provide these specialized services remotely, 
to mitigate the unequal distribution of resources, and to reduce the increasingly high cost of 
health care (Koocher & Morray, 2000; Riemer-Reiss, 2000). Moreover, telepsychotherapy 
opens up the possibility of offering psychological services to people who cannot travel to the 
places where the most effective health care services are located or cannot receive the 
services they need within a reasonable time period (Jerome et al., 2000). It can increase 
timely access to mental health care, while reducing travel, wait lists, and transfers of clients 
to specialized centers. Furthermore, telepsychotherapy makes it easier for local clinics to 
provide their patients in special situations (e.g., linguistic or cultural minorities) with 
psychological services adapted to their needs. Finally, telepsychotherapy can allow for an 
extremely fast reallocation of additional professional resources for crisis situations such as 
natural disasters and mass shootings, which can rapidly overload the locally available 
professional resources. Videoconferencing psychotherapy is thus an innovative intervention 
and it is important to empirically examine its effectiveness before promoting its use.
EFFICACY OF CBT VIA VIDEOCONFERENCE FOR ANXIETY DISORDERS
The efficacy of CBT via videoconference has already been compared to face-to-face 
treatments for various problems including panic attacks (Allard et al., 2007; Bouchard et al., 
2004) and PTSD (Frueh et al., 2007; Germain, Marchand, Bouchard, Drouin, & Guay, 2009; 
Morland, Pierce, & Wong, 2004), and the results suggest that the efficacy of a 
videoconference treatment is equivalent to that of a face-to-face treatment. Frueh et al.’s 
(2007) study and Morland et al.’s (2004) study compared the efficacy of a group CBT with 
veterans via either videoconferencing or face-to-face treatment. Germain et al.’s (2009) 
study assessed individual CBT for PTSD with civilians and showed that individual CBT via 
videoconferencing was as effective as it was face-to-face (n = 24 and n = 44, respectively, 
for the intent-to-treat sample). Participants improved significantly between the beginning 
and the end of their therapy with regard to posttraumatic symptomatology, levels of anxiety 
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and depression, level of functioning in their everyday life, and perception of their physical 
and mental health. However, only the impact of the intervention one week posttreatment was 
published because the follow-up was not completed at that time.
This study presents, for the first time, the follow-up of Germain et al.’s (2009) preliminary 
study, the intent-to-treat results for the whole study (see later), and a new indicator of 
relative efficacy. The first goal is to compare, six months after the end of the psychotherapy, 
the effectiveness of a video-conference administration of a CBT for PTSD to a face-to-face 
administration. The second goal is to present, both for the posttreatment assessment and the 
follow-up assessment, two global indicators of treatment efficacy (proportions of reliable 
changes and of clinically significant changes) and a new indicator called relative efficacy. 
Relative efficacy represents the expected efficacy of videoconference treatments as a 
proportion of the expected efficacy of face-to-face treatments. This index is designed to help 
clinicians, managers, board members, and public agencies make an informed decision when 




Sixty-eight participants with PTSD as a primary diagnosis took part in the study (44 in the 
face-to-face condition and 24 in the videoconference condition). These numbers are larger 
than those published in Germain et al.’s (2009) preliminary study because this article 
includes the non-completers (i.e., the dropouts), whereas the previous article exclusively 
presented results for the completers. However, the two articles refer to the same sample. 
Participants were recruited through public advertisement in newspapers and through 
references from psychiatrists and other health practitioners who knew about one of the two 
anxiety clinics involved in the project. These health practitioners were informed that the 
anxiety clinics provided CBT treatments for individuals diagnosed with PTSD and they gave 
the contact information of the closest of the two anxiety clinics to their patients when they 
judged it relevant. These referring practitioners were not involved in the evaluation, nor in 
the treatment provided at the anxiety clinic. One of the clinics was in Montréal and the other 
was in a remote region. Individuals were excluded from the study if they had a secondary 
diagnosis of schizophrenia, organic brain disorder (e.g., dementia), severe personality 
disorder, intellectual disability, substance abuse or dependency, or a physical condition that 
would contraindicate participation in the study, especially in the videoconferencing 
condition (e.g., epilepsy or vision problems). In addition, each participant had to agree to 
continue using the psychotropic medication already prescribed to him or her and to refrain 
from starting a new psychotropic medication and from participating in any other form of 
psychotherapy during the treatment. This requirement was explained to participants just 
before the signature of the consent form. We did not monitor the participants’ compliance 
with these requirements, but their primary caregiver was informed of the requirements and 
participants were asked to inform their therapist of any subsequent change. All therapists 
administered treatment from Montréal. Because face-to-face treatment was only provided at 
Montréal, a completely random assignment to treatment conditions was impossible. 
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Participants recruited in Montréal were randomly assigned but those in the remote region 
were automatically assigned to the videoconference condition.
A total of 32 of the 44 individuals who were assigned the face-to-face condition (i.e., 73%) 
and 16 of the 24 individuals (i.e., 67%) who were assigned the videoconference condition 
completed the treatment. Out of these, 24 individuals in the face-to-face condition and 12 
individuals in the videoconference condition continued until the follow-up evaluation. The 
complete flowchart of the participants is presented in Figure 1.
No statistical difference was found between the two groups (videoconference vs. face-to-
face) on their pretreatment symptomatology, sociodemographic information, time since 
trauma, or on the proportion of individuals for each type of trauma (p > .05) except for the 
proportion of individuals in a relationship (i.e., married or common law), which was higher 
for those in the face-to-face condition (58% vs. 30%). The characteristics of the sample were 
thus calculated for the whole group (n = 68) instead of separately (n = 44 vs. n = 24). The 
average age was 42.1 years old (SD = 12.1, range = 18–65), 64% of the participants were 
female, and 40% had a university degree (vs. 60% with either a high school or college 
degree). In addition, self-report measures of the treatment expectancies and the therapeutic 
alliance showed equivalent levels for the two treatment modalities (for more details, see 
Germain, Marchand, Bouchard, Guay, & Drouin, 2010). The clinical characteristics of the 
whole sample are presented in Table 1.
Material
Videoconferencing system—The equipment in the therapy room included, at each of 
the two anxiety clinics, an 81-cm television screen, a video camera, a phone, a fax machine, 
and either a Tandberg 2500 or a Tandberg 5000 system. Videoconferencing data were 
transmitted at 384 kilobytes per second and a technician remained available in case of 
technical problems. The fax machine was used to allow the therapist to send and receive 
written material during the therapy (e.g., exercises, schemas, etc.) but all the questionnaires 
were provided on site.
Modified PTSD Symptom Scale—The Modified PTSD Symptom Scale (MPSS 
[French-Canadian version]; Guay, Marchand, Iucci, & Martin, 2002; Resick, Falsetti, 
Resnick, & Kilpatrick, 1991) is a self-administered 17-item questionnaire that measures the 
frequency and severity of PTSD symptoms experienced during the last two weeks. The 
maximum overall score for PTSD is 119. A score of 50 or more is generally the cutoff point 
in determining the presence of PTSD (Guay et al., 2002). The MPSS has excellent internal 
consistency, with an alpha of .97 for the overall scale and .95 for each subscale (frequency 
and severity). It also has excellent construct validity, with a sensitivity level of .97 and a 
specificity level of .90 (Guay et al., 2002). The MPSS was used in this study as the main 
indicator of symptomatology.
The Beck Depression Inventory–Second Edition—The Beck Depression Inventory–
Second Edition (BDI–II [French-Canadian version]; Beck, Steer, Ball, & Ranieri, 1996) 
includes 21 items enumerating depression symptoms. For each item, a list of four statements 
describes different symptom intensity. The respondent chooses the statement best reflecting 
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his or her state over the last seven days. Each item is rated on a scale from 0 to 3, and total 
score ranges from 0 to 63. The BDI–II has been extensively validated and good 
psychometric properties have been reported (Beck et al., 1996; Dozois, Dobson, & Ahnberg, 
1998). For the French version, Cronbach’s alpha is .82 and the 3-month test–retest reliability 
is .75 (Gauthier, Morin, Thériault, & Lawson, 1982). The BDI–II total score was used as a 
secondary indicator of symptomatology for depressive symptoms.
The Beck Anxiety Inventory—The Beck Anxiety Inventory (BAI [French version]; 
Beck & Steer, 1993) is a 21-item self-report questionnaire targeting cognitive and somatic 
symptoms of anxiety. The respondent chooses the statement best reflecting his or her state 
over the last seven days. Each item is rated on a scale from 0 to 3, and total score ranges 
from 0 to 63. This instrument has good psychometric properties (Freeston, Ladouceur, 
Thibodeau, Gagnon, & Rhéaume, 1992). Cronbach’s alphas were .85 to .93 in samples 
suffering from anxiety disorders (Beck & Steer, 1993). The BAI total score was used as a 
secondary indicator of symptomatology for anxious symptoms.
SF-12 Version 2.0 Health Survey—The SF-12 Version 2.0 Health Survey (SF12 
[French version]) is a 12-item self-administered scale assessing perceived health with two 
dimensions, perceived physical health (SF12-physical) and perceived mental health (SF12-
mental; Ware, Kosinski, Turner-Bowker, & Gandeck, 2007). The original English version 
was validated, and 2-week test–retest reliability coefficients are very good (r = .76–.89; 
Ware, Kosinski, & Keller, 1996). The scores were calculated according to the scoring 
method of the SF–12 presented in the User’s Manual for the SF-12v2™ Health Survey and 
the 1998 norms (Ware et al., 2007). The SF12-mental and SF12-physical were used as 
secondary indicators of symptomatology.
Procedure
After being recruited, participants were administered 16 to 25 weekly 60-minute sessions of 
CBT for PTSD, either face-to face or via videoconference. Symptom levels were evaluated 
one month before the intervention, at pre-treatment, at posttreatment, and at the follow-up 
evaluation (six months after treatment). The research project was approved by the Ethics 
Board Committee of the Louis H. Lafontaine Hospital, of the Pierre-Janet Hospital, and of 
the universities involved in the project. The details of the procedure are summarized in this 
section.
Assessment interviews—The first interview began with an explanation of the protocol, 
requirements, and purpose of the project, and signature of the consent form. After that, the 
diagnosis of PTSD was established using a semistructured diagnostic interview, the 
Structured Clinical Interview for DSM–IV (SCID–IV; First, Spitzer, Gibbon, & Williams, 
1995). Interviews were audiotaped. The interrater reliability of the SCID assessment 
between two independent evaluators was evaluated from audiotapes and resulted in a kappa 
of 0.84. This interview also allowed one to assess the presence of comorbid disorders in 
participants. In addition, participants were required to fill out self-report questionnaires. The 
four evaluation interviews (i.e., one month before treatment, at pretreatment, at 
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posttreatment, and for the follow-up at six months) followed the same procedure. The 
assessment interviews were never done by the treating psychologist.
Treatment—Participants in the videoconferencing condition received an average of 21 one-
hour sessions of CBT and those in the face-to-face condition received an average of 19 one-
hour sessions. The therapy consisted of five successive modules: A psychoeducational 
module about PTSD (conceptualization of PTSD, information on normal stress reactions), 
anxiety and stress management training (problem solving, cognitive restructuring, 
progressive relaxation), imaginary exposure to avoided situations, in vivo exposure to 
avoided situations (when relevant), and relapse-prevention strategies (definition of relapse, 
identification of associated risks; Foa, 2000). Therapy was administered by psychologists 
who had an average of 5 years of experience with CBT and in-depth knowledge of PTSD. 
Four psychologists treated most participants and provided therapy to participants in both 
conditions, making it possible to mitigate any potential bias attributable to the therapists. 
Seven other therapists took part in the project more sporadically and each of them treated 
from one to five participants. For logistical reasons, they were only involved in the face-to-
face condition. Supervision by a psychologist with approximately 20 years of experience 
with the treatment of PTSD was also available twice a month for the therapists. All 
therapists were female. The average number of years of experience of the therapists was 
equivalent between conditions. The treatment protocol proposed a specific number of 
sessions for each of the five successive modules, but that number remained partly flexible 
and adapted to each participant’s needs. Sessions were audiotaped to assess therapeutic 
integrity. Integrity was assessed for a random sample of 25% of the treatment sessions and 
included sessions from each of the five successive modules of the psychotherapy (e.g., the 
psychoeducational module, the anxiety and stress management training) to ensure an 
adequate assessment. The assessment of treatment integrity was done by four separate 
evaluators trained in CBT who used a treatment rating chart to assess a subsample of the 
sessions. None of the sessions were assessed by more than one evaluator, so no measure of 
interrater agreement could be calculated. However, there was no statistical difference in the 
average treatment integrity between evaluators, and there was no statistical difference in 
treatment integrity between the two conditions. The mean overall integrity rating was 95%, 
which implies that 95% of the interventions conformed to the treatment protocol (i.e., CBT 
techniques for the treatment of PTSD), and 5% of the interventions did not conform to the 
treatment protocol (e.g., reassurance, passive listening, psychodynamic interpretations, 
distraction).
Analytic procedure—Germain et al.’s (2009) sample exclusively included the 
participants who completed the treatment (i.e., the completers). For this article, the main 
analyses used an intent-to-treat (ITT) approach; that is, they included both completers and 
noncompleters. Readers should thus be careful when comparing number of participants and 
effect sizes between the two. The ITT approach was implemented using the last-observation-
carried-forward method. ITT analyses of treatment effects are considered to provide more 
valid and reliable results than as-treated (AT) analyses (e.g., Ellenberg, 1996). However, for 
a treatment equivalence study such as this one, an ITT approach can also produce a liberal 
bias because it artificially reduces the difference between the two group means. 
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Consequently, AT analyses (i.e., analyses of the completers) were also done to confirm that a 
potential equivalence was not due to a methodological artifact of the ITT approach. 
Preliminary analyses were also done to assess the presence of validity problems with the AT 
analyses.
To compare the effectiveness of the videoconference and the face-to-face treatment after six 
months, a separate analysis of variance (ANOVA) for repeated measures was computed for 
the main indicator of symptomatology (MPSS-total) and for each of the secondary indicators 
of symptomatology. To compare treatment efficacy in more clinical terms, the proportion of 
reliable changes and of clinically significant changes were compared between the two 
conditions both at posttreatment and after six months. Finally, the index of relative efficacy 
was calculated both at posttreatment and after six months to facilitate decisions concerning 




Preliminary analyses confirmed that (a) the proportion of dropouts between the face-to-face 
condition and the videoconference conditions were not statistically different, both at 
posttreatment and follow-up (p > .05), and (b) individuals who dropped out (either before or 
after the posttreatment evaluation) were not statistically different from the others (p > .05) 
on their pretreatment level of symptomatology, sociodemographic information, and the 
proportion of individuals for each type of trauma. Consequently, it was decided that threats 
to the validity were not major enough to prevent the AT analyses to be useful as 
complementary analyses.
Descriptive Statistics
Nearly half (46%) of the participants assigned to the videoconference condition and 48% of 
the participants in the face-to-face condition no longer met the diagnostic criteria for PTSD 
at the posttest (ITT proportions). At the six-month follow-up, the proportion of participants 
who no longer met the diagnostic criteria for PTSD was 33% for the videoconference 
condition and 56% for the face-to-face condition. Group differences were assessed using the 
Newcombe–Wilson method without corrections (Newcombe, 1998) but none was 
statistically significant (p > .05). The size of the symptom reduction effect (i.e., the pretest–
posttest difference) for both videoconference and face-to-face psychotherapy was first 
evaluated for each of the seven outcome variables both at posttreatment and at follow-up 
using an ITT approach (see Table 2 for details). The main AT results are also presented.
Treatment Comparison after Six Months
A separate ANOVA for repeated measures was done on the ITT data for the follow-up on 
each of the seven outcome variables to evaluate if there was a group effect (overall 
videoconference vs. face-to-face differences), a time effect (overall follow-up vs. baseline 
difference), or an interaction (i.e., a differential effect of group over time). As seen in Table 
3, a time effect was systematically found for each outcome (i.e., symptoms are less intense 
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at follow-up than at baseline) but none of the group or interaction effects were statistically or 
clinically significant (i.e., η2 ≤ 0.02) except for the interaction for the SF12-physical, which 
shows a slight advantage for the videoconference condition. Thus, the effects of 
videoconference psychotherapy on symptoms after six months are generally not statistically 
different from the effects of face-to-face psychotherapy on symptoms.
Using the AT data, the ANOVAs produced extremely similar F and p values and slightly 
larger effect sizes (i.e., η2 values), resulting in identical statistical decisions except for the 
interaction for the SF12-physical (p = .07). The quasi-equivalence between the ITT results 
and the AT results supports the idea that the lack of statistically significant differential effect 
of group over time for most symptom scales in the ITT analyses was not due to 
methodological artifacts specific to the ITT procedure.
Clinically Relevant Indicators of Change at Posttreatment and after Six Months
Clinically relevant indicators of change are more and more frequently presented in clinical 
studies in addition to traditional measures of symptom reduction. For this study, both 
Jacobson’s Reliable Change Index (RC) and Clinically Significant Change—criterion C 
(CS) were computed as indicators of change (Jacobson & Truax, 1991). Each indicator was 
computed both for the MPSS-severity and the MPSS-frequency and then averaged between 
the two MPSS subscales to produce a value based on the global MPSS score. The results are 
presented both for the posttreatment and the follow-up and both for the ITT and AT analyses 
(see Table 4). As an example of interpretation (using the ITT results), 38% of the 
participants in the videoconference condition had a clinically significant improvement 
between their pretreatment evaluation and their follow-up evaluation. We could thus expect 
between 21% and 57% of patients to have such a clinically significant improvement in 
similar conditions, with a 95% level of confidence.
Relative Efficacy of Videoconference at Posttreatment and after Six Months
Confidence intervals of the relative efficacy of the videoconference condition were 
calculated to assess the consequences of implementing a videoconference program. Relative 
confidence intervals were calculated for the two most clinically relevant indicators, the main 
outcome variable (MPSS-total) and the Clinically Significant Change. An adaptation of 
Tryon’s (2001) inferential confidence intervals (ICIs) was used, and the confidence intervals 
represent the range of probable values of the decrease (or increase) in efficacy (i.e., mean 
symptom reduction or rate of success) that would result from choosing to implement a 
videoconference program instead of a face-to-face program (the reference group). This 
probability is expressed as a proportion of the efficacy that would be expected from a face-
to-face program in similar conditions (for a similar use of Tryon’s ICI, see Beaulieu-Prévost 
& Zadra, 2007).
To compute the mean of the relative efficacy, we subtracted the face-to-face value from the 
videoconference value and divided the result by the face-to-face value. To compute the 
confidence intervals of the relative efficacy, the steps were to (a) calculate Tryon’s ICI for 
the difference between the two groups (for more details, see Tryon, 2001); (b) calculate the 
lower limit of the confidence interval by subtracting the upper limit of the face-to-face 
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condition from the lower limit of the videoconference condition and dividing the result by 
the upper limit of the face-to-face condition; and (c) calculate the upper limit of the 
confidence interval by subtracting the lower limit of the face-to-face condition from the 
upper limit of the videoconference condition and dividing the result by the lower limit of the 
face-to-face condition. The results are presented in Table 5.
Interpretation and Use of Relative Efficacy Indicators
As mentioned earlier, the data presented in Table 5 can be used to assess the relative efficacy 
of the videoconference condition in comparison to the traditional face-to-face condition and 
to decide whether or not it is an adequate decision to implement a videoconference treatment 
program. However, because this method is new, two examples of interpretations follow. 
First, by using the ITT result of the MPSS-total as the indicator of therapeutic success, it can 
be estimated (with a 95% confidence level) that after six months, choosing to implement 
videoconference treatments would result in the worst case scenario in 50% less symptom 
reduction on average than with a face-to-face treatment program, in the best case scenario in 
85% more symptom reduction on average than with a face-to-face treatment program (i.e., 
nearly twice the efficacy compared to face-to-face treatments), and in the most probable 
scenario in 1% less symptom reduction on average than with a face-to-face treatment 
program. Second, if the ITT result of the CS index is used as the indicator of therapeutic 
success, it can be estimated (with a 95% confidence level) that after six months, choosing to 
implement videoconference treatments would result in the worst case scenario in 53% less 
patients with a clinically significant change than with a face-to-face treatment program, in 
the best case scenario in 58% more patients with a clinically significant change than with a 
face-to-face treatment program, and in the most probable scenario in 10% less patients with 
a clinically significant change than with a face-to-face treatment program. The ITT results 
should be used to assess the relative efficacy of videoconference treatments for a population 
of PTSD patients entering treatment (including those who will eventually drop out of the 
treatment), whereas the AT results should be used to assess the relative efficacy of 
videoconference treatments for those who will continue the treatment until the end.
DISCUSSION
The study shows that the efficacy of a standard CBT for PTSD is equivalent whether done 
face-to-face or by videoconference. The levels of post-traumatic symptoms, anxiety, 
depression, and perceived health improved substantially during treatment in both conditions 
and these gains were maintained after six months. The proportion of dropouts was also 
equivalent between the two conditions, which suggests that the videoconference condition is 
not associated with increased risks of treatment noncompletion. This equivalence between 
videoconference and face-to-face CBT is consistent with the literature (e.g., Bouchard et al., 
2004) and expands on it by showing that it also applies to the treatment of PTSD and that the 
efficacy is maintained for at least six months.
There were still technical difficulties related to the videoconference condition. The signal 
was occasionally interrupted, the quality of the sound and image were suboptimal, and there 
was a short delay between the therapists’ and the clients’ responses. Consequently, the 
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spontaneity of the exchanges was somewhat restricted and the therapists were occasionally 
unsure of their clients’ emotional expression. However, the results of the study demonstrate 
that these difficulties did not interfere with treatment efficacy.
Some elements should still be taken into account before generalizing the results. The main 
limitation is that participants could not be randomly assigned to the treatment condition. 
Preliminary analyses showed that the two groups were equivalent in terms of pretreatment 
symptomatology, therapeutic expectations and alliance, and sociodemographic 
characteristics (except for the proportion of individuals in a relationship), but it is still 
possible that the two groups were not equivalent on potentially important variables not 
measured in this study. In addition, because a small proportion of the therapists were only 
involved in the face-to-face condition, the presence of a therapist effect in the results cannot 
be completely ruled out. Also, even though the main indicators of improvement were quite 
comparable between the two groups, there was a noticeable but statistically nonsignificant 
trend for participants at the six-month follow-up to lose their PTSD diagnosis more 
frequently after a face-to-face therapy (56%) than after video-conference therapy (33%) and 
a slight but statistically nonsignificant trend for face-to-face treatments to be more 
associated with improvement at posttreatment. Thus, randomized treatment studies with 
more participants are still required before a strong argument for the equivalence of 
videoconference and face-to-face treatments of PTSD can be offered.
This study also has important methodological strengths that should be taken into account. It 
used a larger sample than most other studies, the protocol was based on a standardized 
treatment manual and on reliable and valid clinical measures, and it included a six-month 
follow-up. Compared to other videoconference studies on PTSD, this study has the largest 
sample and it is the only one to include a six-month follow-up to assess individual CBT 
(instead of group therapy), and to be done with civilians.
The decision to implement videoconference psychotherapy for PTSD can only be taken on a 
case-by-case basis and it is influenced by factors such as the relative cost and availability of 
each option and by the definition of success used by the decision maker (i.e., symptom 
reduction, rate of reliable changes, rate of clinically significant changes). However, the 
measures of relative efficacy can already inform decision makers about the relative risks and 
advantages of each option because they provide estimations for the worst, average, and best 
case scenarios in terms of relative efficacy. Incidentally, the ITT values and the AT values 
are very similar so the following conclusion applies to both populations.
As mentioned earlier, a replication of this study with a randomized design and a larger 
sample will be necessary before concluding with certainty that videoconferencing is 
equivalent to face-to-face delivery of CBT for PTSD. However, these preliminary results can 
help clinicians, health care managers, and policymakers make informed decisions about the 
use of videoconferencing to treat PTSD. For clinicians, these results suggest that a relatively 
equivalent PTSD symptom reduction could be expected from a videoconference CBT 
treatment and a face-to-face CBT treatment. For health care managers, the results suggest 
that at least in situations in which the cost of implementing videoconference treatments is 
not a major problem, it could potentially be a viable alternative to face-to-face treatments of 
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PTSD in terms of treatment efficiency, especially when adequate face-to-face treatments are 
less available (e.g., in remote and rural areas). For policymakers, making videoconference 
treatments more available as a treatment option in a network of clinics and hospitals (e.g., a 
country’s public health care system) could be a potential solution to improve the efficiency 
and flexibility of the whole network at a structural level.
Whenever possible, it is probably better to keep face-to-face interventions as the primary 
way to deliver psychotherapeutic services, even if treatment equivalence is later confirmed. 
Videoconferencing requires more technical resources (e.g., a technician on site) and is still 
less reliable than face-to-face interventions due to its additional technological complexity 
and reliance on the communication network. It also tends to centralize the resources in the 
health care network compared to face-to-face services. However, considering that 
videoconference CBT treatments are potentially as efficient as face-to-face treatments (at 
least for PTSD), developing CBT videoconferencing resources in a health care network that 
mainly delivers face-to-face services might be an interesting solution to attempt to improve 
the efficiency and flexibility of the health care network.
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TABLE 1
Descriptive Statistics of the Complete Intent-to-Treat Sample
Variable M (SD) or % Range
 Type of trauma 36%
 Physical or sexual aggression 36%
 Traffic accident 22%
 Witnessing to a traumatic event 16%
 Othera 25%
Time since trauma (months) 64.5 (79.4) 1–411
PTSD symptoms
 MPSS (PTSD-specific) 73.1 (22.0) 23–115
 BDI (depression) 28.2 (11.6) 3–56
 BAI (anxiety) 22.4 (12.6) 1–58
Comorbid disorders
 Mood disorders only 24%
 Anxiety disorders only 22%
 Mood and anxiety disorders 16%
 None 37%
Note. n = 68. PTSD = posttraumatic stress disorder; MPSS = Modified PTSD Symptom Scale; BDI = Beck Depression Inventory; BAI = Beck 
Anxiety Inventory.
a
The Other category includes victims of workplace accidents, war veterans, and victims of psychological harassment.



















MARCHAND et al. Page 15
TABLE 2
Mean Symptoms Reduction from Pretreatment and 95% Confidence Intervals at Posttreatment and at Follow-
Up Both for Videoconference and Face-to-Face Cognitive-Behavioral Therapy
Face-to-face Videoconference
M 95% CI M 95% CI
At follow-up (ITT results) n = 32 n = 16
 MPSS-total −23.0 −32.1 to −13.8 −22.8 −34.7 to −10.9
  MPSS-fr −9.5 −13.4 to −5.5 −9.3 −14.1 to −4.6
  MPSS-se −13.5 −18.8 to −8.1 −13.5 −20.8 to −6.1
 BDI −7.2 −11.0 to −3.3 −6.5 −11.7 to −1.3
 BAI −3.7 −7.4 to 0.1 −6.2 −11.9 to −0.4
 SF12-physical 1.8 0.2 to 3.5 5.2 2.4 to 7.9
 SF12-mental 5.5 1.7 to 9.3 4.1 −0.7 to 8.9
At posttreatment (ITT results) n = 23 n = 12
 MPSS-total −24.6 −34.2 to −15.0 −17.6 −29.0 to −6.3
  MPSS-fr −10.4 −14.5 to −6.3 −7.0 −11.6 to −2.4
  MPSS-se −14.2 −19.8 to −8.5 −10.6 −17.6 to −3.7
 BDI −6.7 −11.4 to −2.0 −5.8 −11.2 to −0.4
 BAI −5.0 −8.5 to −1.5 −7.0 −12.7 to −1.3
 SF12-physical 2.5 0.5 to 4.4 5.1 2.0 to 8.2
 SF12-mental 5.8 1.5 to 10.0 4.0 0.0 to 8.0
Main as-treated results
 MPSS-total (follow-up) −33.4 −47.1 to −19.7 −38.1 −58.0 to −18.2
 MPSS-total (posttreatment) −33.8 −45.6 to −21.9 −25.3 42.2 to −8.5
Note. A negative effect implies a symptom reduction except for the SF-12, for which the logic is reversed.
ITT = intent-to-treat; MPSS = Modified PTSD Symptom Scale; BDI = Beck Depression Inventory; BAI = Beck Anxiety Inventory; SF12 = SF-12 
Version 2.0 Health Survey.
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TABLE 4
Rates of Success and 95% Confidence Intervals in Terms of Reliable Change and Clinically Significant 
Change both for Intent-to-Treat (ITT) and As-Treated (AT) Analyses
Face-to-face Videoconference
Success rate 95% CI Success rate 95% CI
At follow-up (ITT) n = 32 n = 16
 Reliable change 55% 40–69% 56% 37–74%
 Clinically significant change 42% 28–57% 38% 21–57%
At posttreatment (ITT) n = 23 n = 12
 Reliable change 55% 40–69% 48% 30–67%
 Clinically significant change 47% 33–61% 33% 18–53%
At follow-up (AT) n = 32 n = 16
 Reliable change 74% 54–87% 87% 57–97%
 Clinically significant change 57% 37–75% 52% 27–76%
At posttreatment (AT) n = 23 n = 12
 Reliable change 73% 55–85% 71% 47–88%
 Clinically significant change 61% 44–77% 49% 27–71%
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TABLE 5
Relative Efficacy and 95% Confidence Intervals of Videoconference Compared to Face-to-Face in Terms of 
MPSS Total Score and Clinically Significant Change
At posttreatment At follow-up
Efficacy 95% CI Efficacy 95% CI
Intent-to-treat results
 MPSS-total −28% −68 to +41% −1% −50 to +85%
 Clinically significant change −28% −63 to +26% −10% −53 to +58%
As-treated results
 MPSS-total −25% −66 to +42% +14% −40 to +110%
 Clinically significant change −21% −57 to +30% −9% −51 to +60%
Note. MPSS = MPSS = Modified PTSD Symptom Scale.
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